KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Amortizatization of Intangibles (2016 - 2023)

Historic Amortizatization of Intangibles for Travere Therapeutics (TVTX) over the last 13 years, with Q4 2023 value amounting to $2.3 million.

  • Travere Therapeutics' Amortizatization of Intangibles rose 12238.51% to $2.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $5.7 million, marking a year-over-year increase of 71742.86%. This contributed to the annual value of $4.5 million for FY2024, which is 3917.65% down from last year.
  • As of Q4 2023, Travere Therapeutics' Amortizatization of Intangibles stood at $2.3 million, which was up 12238.51% from $1.9 million recorded in Q3 2023.
  • Travere Therapeutics' 5-year Amortizatization of Intangibles high stood at $2.3 million for Q4 2023, and its period low was -$697000.0 during Q4 2021.
  • Moreover, its 5-year median value for Amortizatization of Intangibles was -$155500.0 (2020), whereas its average is $161333.3.
  • As far as peak fluctuations go, Travere Therapeutics' Amortizatization of Intangibles surged by 29509.8% in 2019, and later crashed by 202222.22% in 2020.
  • Travere Therapeutics' Amortizatization of Intangibles (Quarter) stood at $9000.0 in 2019, then tumbled by 2022.22% to -$173000.0 in 2020, then tumbled by 302.89% to -$697000.0 in 2021, then soared by 246.77% to $1.0 million in 2022, then skyrocketed by 122.39% to $2.3 million in 2023.
  • Its Amortizatization of Intangibles stands at $2.3 million for Q4 2023, versus $1.9 million for Q3 2023 and $1.0 million for Q4 2022.